오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 426.4 mg (equivalent: lidocaine hydrochloride, qty 400 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.64 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 106.6 mg (equivalent: lidocaine hydrochloride, qty 100 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty 5 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.